Ceva inaugurates first autovaccine reference site in Europe

Veterinary autogenous vaccines will be manufactured and researched at site in Pays de la Loire region of France.

September 30, 2020

2 Min Read
Ceva inaugurates first autovaccine reference site in Europe

A year after the presentation of its global hub for companion animal innovation in Laval, France, Ceva Santé Animale, a leading veterinary biopharmaceutical company based in France, announced that it is once again reinforcing its regional stronghold.

On Sept. 29, Ceva inaugurated its first European benchmark site near Angers, France, for the design and industrial manufacturing of bacterial autovaccines (also known as autogenous vaccines), primarily for pigs and poultry.

The Angers-based Biovac laboratory, a leader in French bacterial autovaccines and reagents, has been part of Ceva since June 2016. The site became Ceva Biovac and has invested more than 8 million euros (16% of which was subsidized by the Regional Council of Pays de la Loire) for it to become a European reference site at the forefront of innovation.

Ceva Biovac's aim is to fight infectious diseases in farming and offer an alternative to antibiotics by developing the manufacturing and industrial production of veterinary bacterial autovaccines. Autovaccines are a custom solution for veterinarians and farmers manufactured directly from disease strains collected from animals on a specific farm, Ceva explained.

Ceva Biovac is equipped with the highest-performing biological technologies, bringing optimal security and surpassing all European and international regulations. The tailored manufacturing offers flexibility in terms of the size of batches (one to 200 liters) and a production capacity of 300 batches per week.

Today, Ceva owns four sites dedicated to autovaccines around the world — in Germany, Canada, the U.S. and the U.K. — although the goal of the Ceva Biovac campus in Angers is to become a test site in terms of process and research and development that will, in turn, be replicated internationally, Ceva said.

“Ceva is firmly committed to prevention. Vaccines represent almost 50% of our portfolio of products. This strategy illustrates our efforts in the fight against [antibiotic resistance] and aims to place veterinarians at the heart of the fight against microbial diseases. Along with vaccines, autovaccines are an alternative to medication and a major tool for reducing the use of antibiotics in the livestock sector,” Ceva Santé Animale chairman and chief executive officer Dr. Marc Prikazsky said.

Subscribe to Our Newsletters
Feedstuffs is the news source for animal agriculture

You May Also Like